The new marketing arrangement between Schering-Plough Corp. and Bayer AG [See Deal] gives Schering additional products it can sell along with its recently approved Vytorin (the cholesterol drug that combines Schering's ezetimibe (Zetia) and Merck & Co. Inc. 's simvastatin [Zocor]). It also adds a significant number of reps from Bayer to help it do so. The deal reinforces Schering's commitment to building a primary care franchise, a cornerstone of CEO Fred Hassan's turnaround plan for the company. But it runs counter to an emerging trend among many Big Pharmas to focus increasingly on higher-value specialist markets, which do not require a huge sales and marketing infrastructure—or the regular flow of new primary-care products necessary to support them.
In Pursuit of Primary Care, Schering-Plough Is Growing against the Grain
The marketing deal between Schering-Plough and Bayer gives Schering additional products it can sell along with its recently approved cholesterol drug Vytorin, and a significant number of reps to help it do so. As such, the deal reinforces Schering's commitment to building a primary care franchise. But it also runs counter to an emerging trend among many Big Pharmas to focus increasingly on higher-value specialist markets, which do not require a huge sales and marketing infrastructure--or the regular flow of new primary-care products necessary to support it.
More from Business Strategy
More from In Vivo
Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.